Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
-
Field
-
Status Full-time Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No Offer Description
-
Programme? Horizon Europe - ERC Is the Job related to staff position within a Research Infrastructure? No Offer Description Postdoctoral Position in attosecond chiroptical coincidence spectroscopy
-
) Country Switzerland Type of Contract Temporary Job Status Full-time Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a
-
can be found on our website (https://www.epfl.ch/campus/services/human-resources/en/basic-starting-salary-of-doctoral-assistants-and-postdocs/) Opportunity to perform state-of-the-art research in one
-
Musicology Lab, EPFL Lausanne Mission Profil PhD (or nearing completion of) in …. Background in…. Research experience in ... Strong computational and analytical skills… Experimental skills and experience in
-
) Application Deadline 15 Sep 2026 - 21:59 (UTC) Country Switzerland Type of Contract Permanent Job Status Full-time Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is
-
24 Jun 2026 Job Information Organisation/Company ETH Zürich Research Field Biological sciences » Other Computer science » Other Medical sciences » Other Researcher Profile Recognised Researcher (R2
-
our expanding in vivo and ex vivo neuroscience program, we are seeking a motivated and experienced technician to assist with mouse work, surgical procedures, and primary neuron culture. Main duties and
-
, OSDI). We are looking for a candidate who is comfortable "looking under the hood" of the operating system. You do not need prior experience with optics. PhD/Masters in Computer Science, Electrical
-
protocols. In close collaboration with the lab of George Coukos (https://agora-cancer.ch/laboratory/coukos-lab/ ), we will derive protocols enabling rapid expansion of cancer-specific, autologous TILs